Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.68 |
| ▸ | PDE4A | P27815 | 3/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508639 | 0.85 | PDE4D (0.69) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL186917 | 0.80 | PDE4A (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL508869 | 0.79 | PDE4D (0.56) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10164955 | 0.78 | PDE4D (0.65) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL509121 | 0.78 | PDE4D (1.00) | PDE4D | |
| SCHEMBL508816 | 0.77 | PDE4D (0.75) | PDE4DPDE4A | |
| SCHEMBL187090 | 0.77 | PDE4A (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL187315 | 0.77 | PDE4A (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10203335 | 0.77 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL508443 | 0.77 | PDE4D (0.64) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| EP-2146989-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE5A, PDE3A, PDE3B | PDE4D 9/4885PDE4A 6/4885PDE4B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.